Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1998-05-29
2000-11-28
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4352351, A61K 3912, C12N 700
Patent
active
061532010
ABSTRACT:
The present invention is directed to a method of expressing the papillomavirus capsid protein coding sequence in a cell using an expression system under conditions facilitating expression of the protein in the cell. In another aspect of the invention, it has been discovered that virus-like particle(s) (VLPs), fragment(s), capsomer(s) or portion(s) thereof are formed from the papillomavirus capsid protein. It was further discovered that the virus-like particle(s) comprises antigenic characteristics similar to those of native infectious papillomavirus particles. In one embodiment of the invention, there is provided a method of expressing the L1 major capsid protein of human papillomavirus type-6 (HPV-6) and type-11 (HPV-11) in Sf-9 insect cells using the baculovirus expression system, and the production of type 6 (HPV-6), type-11 (HPV-11), type-16 (HPV-16) and type-18 (HPV-18) virus-like particles. In yet another embodiment, the invention provides a method of vaccinating a mammal for papillomavirus by administering papillomavirus virus-like particles orally to a mammal in an amount sufficient to induce an immune response to the papillomavirus.
REFERENCES:
patent: 4777349 (1988-10-01), Schoolnik et al.
patent: 4870023 (1989-09-01), Fraser et al.
patent: 5041385 (1991-08-01), Kingsman et al.
patent: 5045447 (1991-09-01), Minson
patent: 5057411 (1991-10-01), Lancaster et al.
patent: 5071757 (1991-12-01), Kreider et al.
patent: 5169766 (1992-12-01), Schuster et al.
patent: 5346811 (1994-09-01), Galindo-Castro et al.
patent: 5437951 (1995-08-01), Lowy et al.
Reichman et al., "Papillomaviruses," in Mandell et al., eds. Principles and Practice of Infectious Diseases, 3.sup.rd Ed., New York, New York:Churchill Livingstone, pp. 1191-1200 (1990).
Crum et al., "Human Papillomavirus Infection and Cervical Neoplasia: New Perspectives," Int. J. Gynecol. Pathol., 3:376-388 (1984).
Zur-Hausen, "Genital Papillomavirus Infections," in Rigby, eds., Virues and Cancer, Cambridge, UK:Cambridge University Press, pp. 83-90 (1985).
Koutsky et al., "Epidemiology of Genital Human Papillomavirus Infection," Epidemiol. Rev., 10:122-163 (1988).
Bonnez et al., "The PstI-XhoII Restriction Fragment of the HPV-6b L1 ORF Lacks Immunological Specificity as Determined by SERA from HPV 6 Condyloma Acuminatum Patients and Controls," in Howley, eds., Papillomaviruses: UCLA Symp. Mol.Cell Biol.,New Series, vol. 124, New York, New York:Wiley-Liss, Inc., pp. 77-80 (1990).
Jenison et al., "Identification of Immunoreactive Antigens of Human Papillomavirus Type 6B by Using Escherichia coli--Expressed Fusion Proteins," J. Virol., 62:2115-2123 (1988).
Li et al., "Identification of the Human Papillomavirus Type 6b L1 Open Reading Frame Protein in Condylomas and Corresponding Antibodies in Human Sera," J. Virol., 61:2684-2690 (1987).
Steele et al., "Humural Assays of Human Sera to Disrupted and Nondisrupted Epitopes of Human Papillomavirus Type 1," Virology, 174:388-398 (1990).
Strike et al., "Expression in Escherichia coli of Seven DNA Segments Comprising the Complete L1 and L2 Open Reading Frames of Human Papillomavirus Type 6b and the Localization of the `Common Antigen Region,`" J. Gen. Virol., 70:543-555 (1989).
Kienzler et al., "Humoral and Cell-Mediated Immunity to Human Papillomavirus Type 1 (HPV-1) in Human Warts," Br. J. Dermatol., 108:665-672 (1983).
Pfister et al., "Seroepidemiological Studies of Human Papilloma virus (HPV-1) Infections," Int. J. Cancer, 21:161-165 (1978).
Kreider et al., "Laboratory Production In vivo of Infectious Human Papillomavirus Type 11," J. Virol., 61:590-593 (1987).
Kreider et al., "Morphological Transformation In vivo of Human Uterine Cervix with Papillomavirus from Condylomata acuminata," Nature, 317:639-641 (1985).
Zhou et al., "Expression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Viron-like Particles," Virology, 185:251-257 (1991).
Biberstein, "Immunization Therapy of Warts," Arch. Dermatol Syphilol, 50:12-22 (1944).
Powell et al., "Treatment of Condyloma acuminata by Autogenous Vaccine," South Med. J., 63:202-205 (1970).
Malison et al., "Autogenous Vaccine Therapy for Condyloma acuminatum: A Double-Blind Controlled Study," Br. J. Vener. Dis., 58:62-65 (1982).
Gissmann et al., "Human Papillomaviruses and Cervical Cancer," Cancer Cells, 5:275-280 (1987).
Bonnez et al., "Use of Human Papillomavirus Type 11 Virions in an Elisa to Detect Specific Antibodies in Humans with Condylomata acuminata," J. Gen. Virol., 72:1343-1347 (1991).
Rose et al., "Expression of the Full-Length Products of the Human Papillomavirus Type 6b (HPV-6b) and HPV-11 L2 Open Reading Frames by Recombinant Baculovirus, and Antigenic Comparisons with HPV-11 Whole Virus Particles," J. Gen. Virol., 71:2725-2729 (1990).
Bonnez et al., "Antibody-Mediated Neutralization of Human Papillomavirus Type 11 (HPV-11) Infection in the Nude Mouse: Detection of HPV-11 mRNAs," J. Inf. Dis., 165:376-380 (1992).
Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas A&M University College Station, Texas (1987).
Laemmli, "Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4," Nature, 227:680-685 (1970).
Stoscheck, "Quantitation of Protein," Abelson, eds., Methods in Enzymology, vol. 182, New York, New York:Academic Press, Inc., pp. 50-68 (1990).
Stanley et al., "Construction of a New Family of High Efficiency Bacterial Expression Vectors: Identification of cDNA Clones Coding for Human Liver Proteins," The EMBO J., 3(6):1429-1434 (1984).
Klug et al., "Structure of Viruses of the Papilloma-polyoma Type I. Human Wart Virus," J. Mol. Biol., 11:403-423 (1965).
Bonnez et al., "Evolution of the Antibody Response to Human Papillomavirus Type 11 (HPV-11) in Patients with Condyloma Acuminatum According to Treatment Response," J. Med. Virol., 39:340-344 (1993).
Christensen et al., "Detection of Human Serum Antibodies that Neutralize Infectious Human Papillomavirus Type 11 Virions," J. Gen. Virol., 73:1261-1267 (1992).
Christensen et al., "Antibody-Mediated Neutralization In vivo of Infectious Papillomaviruses," J. Virol., 64(7):3151-3156 (1990).
Shaw et al., "A Conserved AU Sequence from the 3' Untranslated Region of GM-CSF mRNA Mediates Selective mRNA Degradation," Cell, 46:659-667 (1986).
Cole et al., "cis-Acting Determinants of c-myc mRNA Stability," Enzyme, 44:167-180 (1990).
Shyu et al., "Two Distinct Destabilizing Elements in the c-fos Message Trigger Deadenylation as a First Step in Rapid mRNA Decay," Genes & Development, 5:221-231 (1991).
Savant-Bhonsale et al., "Evidence for Instability of mRNAs Containing AUUUA Motifs Mediated Through Translation-Dependent Assembly of a > 20S Degradation Complex," Genes & Development, 6:1927-1939 (1992).
Kirnbauer et al., "Papillomavirus L1 Major Capsid Protein Self-Assembles Into Virus-like Particles that are Highly Immunogenic," Proc. Natl. Acad. Sci. USA, 89:12180-12184 (1992).
Carter et al., Expression of Human Papillomavirus Proteins in Yeast Saccharomyces cerevisiae, Virology, 182:513-521 (1991).
Karasuyama et al., Establishment of Mouse Cell Lines Which Constitutively Secrete Large Quantities of Interleukin 2, 3, 4 or 5, Using Modified cDNA Expression Vectors, Eur. J. Immunol. 18:97-104 (1988).
Xi et al., "Baculovirus Expression of the Human Papillomavirus Type 16 Capsid Proteins: Detection of L1-L2 Protein Complexes," J. Gen Virology, 72:2981-2988 (1991).
Hagensee et al., "Self-Assembly of Human Papillomavirus Type 1 Capsids by Expression of the L1 Protein Alone or by Coexpression of the L1 and L2 Capsid Proteins," J. of Virology, 67(1):315-322 (1993).
Rose et al., "Expression of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles," J. of Virology, 67(4):1936-1944 (1993).
Rose et al., "Serological Differentiation of Human Papillomavirus Types 11, 16, and 18 Using Recombinant Virus-Like Particles," J. of Gen Virology, 75:2445-2449 (1994).
Rose et al., "Human Papillomavirus Type 11 (HPV-11) Virus-
Rose Robert C.
Rybicki Edward P.
Williamson Anna-Lise
Mosher Mary E.
University of Cape Town
University of Rochester
LandOfFree
Oral immunization with papillomavirus virus-like particles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral immunization with papillomavirus virus-like particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral immunization with papillomavirus virus-like particles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1722184